

सं./ No. 31026/16/2020-Policy
भारत सरकार / Government of India
रसायन और उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers
औषध विभाग / Department of Pharmaceuticals

उद्योग भवन, नई दिल्ली – 110 001
Udyog Bhawan, New Delhi – 110 001
Dated 26th November 2025

Notice

Subject: Invitation of applications for eligible products under the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in the country

The Department of Pharmaceuticals invites applications for the eligible products, Meropenem and Ritonavir, under the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in the country. Various conditions under the scheme, such as allocation according to available capacities, incentive ceiling in respect of products and limit of incentive up to the production tenure, *i.e.*, up to FY2027-28 for chemical synthesis products, would have to be complied with. Further, applicants — including their group companies or subsidiaries — who had previously applied under the scheme for the same unsubscribed products and were granted approval, but who subsequently withdrew from the scheme or whose approval was cancelled in line with clause 12.11 of the scheme guidelines (amended to clause 12.13 *vide* corrigendum dated 12.3.2024) owing to non-performance or other reasons, are not eligible to apply for the same eligible product.

2. Accordingly, applications are invited for the following eligible products:

S. no.	Target segment	Name of eligible product	Minimum annual production capacity as per scheme guidelines (in MT)	Total available production capacity (in MT)	Maximum number of applicants to be selected
1	Other chemical synthesis based KSMs/DIs/APIs	Meropenem	4	16	4
2	Other Chemical Synthesis based KSMs/DIs/APIs	Ritonavir	5	20	4

3. The eligible applicants may apply through online mode only (<https://plibulkdrugs.ifcilttd.com>) from 27.11.2025 to 26.12.2025. Detailed guidelines of the scheme and necessary corrigendum are available at <https://pharma-dept.gov.in/schemes>.

Encl.: as above


26/11/2025

(सुहास भुइयां) (Suhas Bhuyan)

अवर सचिव, भारत सरकार

Under Secretary to the Government of India

दूरभाष / Tel: 23062531

Email: US-PharmaSchemes@pharma-dept.gov.in

To:

API manufacturers and eligible industries under the PLI scheme for Bulk Drugs

Copy to:

1. Director (Advisory Services), IFCI Limited, IFCI Tower, 61, Nehru Place, New Delhi – 110 019, for further action to open the application window for 30 days from 27.11.2025
2. Head of Group, Department of Pharmaceuticals Informatics Division, National Informatics Centre — with a request to upload this notice on the website of the Department of Pharmaceuticals